Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.
Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...
News Medical on MSN8d
Study highlights potential of genomic tests for early stage prostate cancerA new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback